NCT05007873 2026-02-18
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
1 trialsLeukemia, Myeloid, Chronic-Phase × decitabine and cedazuridine drug combination × 90 days × Clear all